- Molecular NameFexofenadine
- SynonymCarboxyterfenadine; Fexofenadine hydrochloride; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; Terfenadine-COOH
- Weight501.667
- Drugbank_IDDB00950
- ACS_NO83799-24-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.58
- pka4.25 and 9.53
- LogD (pH=7, predicted)2.08
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-2.3
- LogSw (predicted, AB/LogsW2.0)0.07
- Sw (mg/ml) (predicted, ACD/Labs)2.49
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds10
- TPSA81.0
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antihistamine drug used in the treatment of hayfever and similar allergy symptoms.
- Absorption_valueN/A
- Absorption (description)Fexofenadine is rapidly absorbed after oral administration. A substrate for hepatic and intestinal P-glycoprotein efflux transporter
- Caco_2N/A
- Bioavailability33.0
- Protein binding65.0
- Volume of distribution (VD)5.6 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- Metabollsm5% of a dose is metabolised by intestinal mucosa, 0.5 to 1.5 % undergoes hepatic biotransformation.
- Half life14 h
- ExcretionThe drug is mainly excreted in faeces unchanged (80%) and 10% in urine. Fexofenadine is a metabolite of terfenadine and therefore has been detected in breast milk after administration of terfenadine. Fexofenadine does not cross the blood–brain barrier.
- Urinary Excretion12
- Clerance9.4 ml/min/kg
- ToxicitySide effects include dizziness, drowsiness, and dry mouth.
- LD50 (rat)N/A
- LD50 (mouse)N/A